John Shannon

Biography

John Shannon has 30+ years of pharmaceutical and healthcare experience with a diverse background in sales, global and US marketing, operations and manufacturing, strategic planning and business development. Most recently, Mr. Shannon spent 2 years as Chief Executive Officer for Catheter Connections, Inc.(CCI). CCI developed and commercialized innovative vascular access products designed to protect patients from acquiring infections during intravenous infusion therapy. Its DualCap System™ is a family of user-friendly products that provides healthcare facilities with a cost-effective, integrated solution for IV disinfection and protection, helping in the fight against IV catheter-related blood stream infections. CCI was acquired by Merit Medical in January of 2016. Prior to CCI, Mr. Shannon spent 3 years as Chief Commercial Officer for Durata Therapeutics. Durata Therapeutics was an innovative new pharmaceutical company focused on the development and commercialization of differentiated therapeutic solutions to advance patient care in infectious disease and acute illnesses. Durata was acquired by Actavis for ~$675 million, December 2014. Prior to that, Mr. Shannon spent 10 years at Baxter Healthcare where he was General Manager, Global Hemophilia and Global Commercial Excellence, General Manager, US Biopharmaceuticals, Vice President Marketing US Bioscience and Vice President Marketing US Renal. During his time at Baxter he led the commercialization and drove the growth of two Baxter brands, Advate and Gammagard, both which now exceed billion + dollars each. Prior to coming to Baxter, he was Vice President, Marketing for Caremark. Before that he was at Searle for 10 years where he held several positions most importantly, Executive Director, Cardiovascular Global Commercialization, responsible for the commercial development and marketing of new cardiovascular products worldwide and the Sr. Director of Cox-2 Global Commercialization, where he lead the worldwide launch and global marketing of Celebrex. In addition, he spent 7 years at Bock Pharmacal Company where he held various positions including Sales Representative, Sales Trainer, Sales Operations, Marketing, Strategic Planning and Business Development. John has Bachelor of Science degree in Biology, emphasis in microbiology, from Western Illinois University.

Research Interest

Durata Therapeutics was an innovative new pharmaceutical company focused on the development and commercialization of differentiated therapeutic solutions to advance patient care in infectious disease and acute illnesses. Durata was acquired by Actavis for ~$675 million, December 2014. Prior to that, Mr. Shannon spent 10 years at Baxter Healthcare where he was General Manager, Global Hemophilia and Global Commercial Excellence, General Manager, US Biopharmaceuticals, Vice President Marketing US Bioscience and Vice President Marketing US Renal. During his time at Baxter he led the commercialization and drove the growth of two Baxter brands, Advate and Gammagard, both which now exceed billion + dollars each. Prior to coming to Baxter, he was Vice President, Marketing for Caremark. Before that he was at Searle for 10 years where he held several positions most importantly, Executive Director, Cardiovascular Global Commercialization, responsible for the commercial development and marketing of new cardiovascular products worldwide and the Sr. Director of Cox-2 Global Commercialization, where he lead the worldwide launch and global marketing of Celebrex. In addition, he spent 7 years at Bock Pharmacal Company where he held various positions including Sales Representative, Sales Trainer, Sales Operations, Marketing, Strategic Planning and Business Development. John has Bachelor of Science degree in Biology, emphasis in microbiology, from Western Illinois University.